Clinical Trial Update: A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

This Clinical Trial Update reports on a completed Phase 1/2 study of MDV3100 (enzalutamide) in prostate cancer to evaluate safety, tolerability, pharmacokinetic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• MDV3100 (enzalutamide) (enzalutamide)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Prostate Cancer, Prostate Neoplasms | Phase 1, Phase 2 | Status: COMPLETED